stonks4u
Sign up free
CLRB logo

CLRB Cellectar Biosciences, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$2.60
+0.12 (+4.84%)

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstr…

Market Cap: $20.77Mwww.cellectar.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

95
95
Aug 13Aug 13

Quote

Day Range
$2.56 – $2.64
52-Week Range
$2.20 – $6.52
Volume
$46.3K
Market Cap
$20.77M
50-Day Avg
$2.56
200-Day Avg
$2.99
Prev Close
$2.48
Open
$2.56

Valuation & Ratios

P/E Ratio
-0.35
EPS
$-8.35
P/B Ratio
0.78
P/S Ratio
0.00
Debt/Equity
0.04
Current Ratio
2.96
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-219.7%
Return on Assets
-145.5%
FCF Yield
-300.5%
EV/EBITDA
0.24

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-21.79M$-8.35
2024$0.00$-44.58M$-36.52
2023$0.00$-42.77M$-104.99
2022$0.00$-31.79M$-135.18
2021$0.00$-24.12M$-130.35

Social Signal Score

46
5d
46
2 mentions
—
30d
46
2 mentions
—
60d
46
2 mentions
—
90d
46
2 mentions
—
news: 2

Earnings

Thu, Nov 12(in 3 months)

Consensus estimate $-0.46 per share

6of 7 quarters beat consensus

Typical surprise +26.2% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$-0.57 vs $-0.52miss
  • Thu, May 14$-1.33 vs $-1.89beat
  • Wed, Mar 4$-0.53 vs $-1.19beat
  • Thu, Nov 13$-1.41 vs $-1.91beat
  • Thu, Aug 14$-3.39 vs $-3.60beat
  • Tue, May 13$-3.90 vs $-5.11beat

Estimates and results for CLRB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

CLRBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsseekingalpha.com·2d ago·Positive

    Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript

    View source ↗
  • Newsglobenewswire.com·2d ago·Negative

    Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program

    View source ↗